Drug Approval | November 08, 2023
Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin’s Pithampur facility in India
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Subscribe To Our Newsletter & Stay Updated
